

Calycosin-7-O- β -D-glucoside attenuates ischemia-reperfusion injury *in vivo* via activation of the PI3K/Akt pathway

MIN REN, XUDONG WANG, GUOQING DU, JIAWEI TIAN and YUJIE LIU

Department of Medical Ultrasonics, The Second Affiliated Hospital of Harbin Medical University,
Harbin, Heilongjiang 150086, P.R. China

Received December 25, 2014; Accepted August 22, 2015

DOI: 10.3892/mmr.2015.4611

Abstract. The aim of the present study was to investigate the effects and mechanisms of calycosin-7-O- β -D-glucoside (CG) on ischemia-reperfusion (I/R) injury *in vivo*. Hemodynamic parameters, including ejection fraction (EF), fractional shortening (FS), left ventricular end-systolic pressure (LVESP) and left ventricular end-diastolic pressure (LVEDP) were monitored using an ultrasound system, and infarct size was measured using Evans blue/tetrazolium chloride double staining. The activities of serum creatine kinase (CK), lactate dehydrogenase (LDH) and superoxide dismutase (SOD), and the levels of malondialdehyde (MDA) were determined to assess the degree of myocardial injury and oxidative stress-induced damage. The protein expression levels of cleaved-caspase-3, cleaved-caspase-9, phosphorylated (p)-phosphatidylinositol 3-kinase (PI3K) p85, PI3K p85, p-Akt and Akt were determined using western blotting. The results demonstrated that pretreatment with high dose (H)-CG markedly improved cardiac function, as evidenced by upregulated EF, FS and LVESP, and downregulated LVEDP. In addition, administration of CG resulted in significant decreases in infarct size in the I/R+low dose-CG and I/R+H-CG groups, compared with the I/R group. The activities of CK and LDH, and the levels of MDA in the I/R+H-CG group were reduced, compared with those in the I/R group, whereas SOD activity was elevated. Treatment with CG inhibited the cleavage and activity of caspase-3 and caspase-9, and enhanced the phosphorylation of PI3K p85 and Akt. Notably, administration of the PI3K inhibitor, LY294002, markedly lowered the levels of p-PI3K p85/p-Akt, and eradicated the inhibitory effects of H-CG on infarct size, myocardial

injury and oxidative stress-induced damage. Taken together, the results suggested that CG may alleviate I/R injury by activating the PI3K/Akt signaling pathway.

Introduction

Acute myocardial infarction (AMI) is associated with high mortality rates worldwide (1). AMI often occurs due to rupture of an atherosclerotic plaque in a coronary artery, which may induce thrombosis and artery occlusion, resulting in loss of blood supply to the affected area and necrosis. Annually, over 3,000,000 individuals suffer from acute ST-elevation myocardial infarction, and over 4,000,000 individuals suffer from non-ST-elevation myocardial infarction (2). Currently, the therapeutic strategies considered most effective are mechanical revascularization by percutaneous coronary intervention (3), thrombolytic therapy (4), primary angioplasty (5), coronary artery bypass grafting and antithrombotic therapy combined with timely reperfusion (6). However, these treatments are unable to improve cardiac function (7). In addition, tissue ischemia followed by reperfusion initiates systemic inflammation, which may aggravate local injury and induce remote multi-organ dysfunction (8). Therefore, the development of a safer, more effective strategy for reducing I/R injury and improving postoperative survival rates is required.

Astragali Radix (AR), the root of *Astragalus membranaceus* and *Astragalus membranaceus* var. *mongholicus* (9), is a traditional Chinese medicine (10). AR exerts various bioactivities, including antioxidation, enhancement of cardiovascular function, hepatoprotection, immunostimulation and myocardial protection in diabetic nephropathy (11). AR has also been reported to reduce myocardial ischemic injury (12), and AR extracts efficiently protect MRC-5 cells from H₂O₂-induced oxidative damage via the inhibition of superoxide dismutase (SOD) and catalase (13). A previous clinical report indicated that AR may be a promising agent in the treatment of acute cerebral infarction (14). AR contains various active components, including polysaccharides, flavonoids, astragalosides I-VII (saponins), amino acids and trace elements (15,16). Calycosin-7-O- β -D-glucoside (CG) is a predominant flavonoid of AR (17-19), which is known to possess anti-inflammatory (20) and anti-osteoarthritic properties (21). A previous study has shown that CG significantly reduces cerebral infarct size and histological damage in a rat model of I/R. In addition, CG protects blood-brain barrier integrity by inhibiting

Correspondence to: Dr Yujie Liu or Dr Jiawei Tian, Department of Medical Ultrasonics, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, Heilongjiang 150086, P.R. China

E-mail: liuyujiezk@163.com

E-mail: jiaweitianjw@126.com

Key words: calycosin-7-O- β -D-glucoside, ischemia-reperfusion injury, cardiac function, infarct size, caspase, phosphatidylinositol 3-kinase/Akt pathway

the activities of matrix metalloproteinases, scavenging nitric oxide and promoting the expression of caveolin-1 (22). However, the effects of CG on myocardial I/R injury and the underlying mechanisms remain to be fully elucidated.

In the present study, a rat model of myocardial I/R injury was treated with CG, and the underlying molecular mechanisms of CG on myocardial I/R injury were evaluated.

Materials and methods

Animals. Male Wistar rats (8-week-old) were purchased from Charles River Laboratories (Beijing, China). Experiments were performed according to the guidelines for the animal care and use of laboratory animal protocols, and were approved by the Ethics Committee of The Second Affiliated Hospital of Harbin Medical University (Harbin, China; approval no. SCXK-2012-0001). The rats were maintained in an air-conditioned room with a constant temperature of 22°C and an alternating 12 h light/12 h dark cycle. The rats were provided with access to water and a standard diet *ad libitum*.

In vivo myocardial I/R model and experimental groups. The rats were anesthetized with 10% chloral hydrate (3 ml/kg body weight; Sinopharm Medicine, Shenyang, China) by intraperitoneal injection. The rats were intubated, and mechanical ventilation was achieved by connecting the endotracheal tube to a scientific ventilator (HX-300S; Chengdu Technology & Market Co., Ltd, Chengdu, China) at a respiratory rate of 80 breaths/min with a tidal volume of 6–8 ml/kg body weight. A left thoracotomy was performed, in order to expose the heart and the root of the large blood vessel. The left anterior descending (LAD) coronary artery was subsequently transiently ligated with a nylon suture for a 45 min ischemic period. Microsurgical scissors were used to release the ligature, and the heart was reperfused for 3 h.

The rats were randomly divided into five groups (12 animals per group). In the sham group, the rats underwent the described anesthetic and surgical procedures without ligation of the LAD coronary artery; in the I/R group, the rats underwent myocardial ischemia for 45 min and reperfusion for 3 h by ligation of the LAD coronary artery; in the I/R+H-CG group, the rats were pretreated with a high dose of CG (H-CG; 30 mg/kg body weight; Dalian Meilun Biological Technology Co., Ltd., Dalian, China) via intravenous injection 30 min prior to ligation of the LAD coronary artery; in the I/R+L-CG group, the rats were pretreated with a low dose of CG (L-CG; 15 mg/kg body weight) via intravenous injection 30 min prior to ligation of the LAD coronary artery; in the sham+H-CG group, the rats were pretreated with H-CG via intravenous injection, and then underwent the described anesthetic and surgical procedures without ligation of the LAD coronary artery.

Detection of cardiac function. Following reperfusion, an ultrasound system (IE33; Philips GmbH, Herrsching, Germany) was used to collect hemodynamic parameters, including ejection fraction (EF), fractional shortening (FS), left ventricular end-systolic pressure (LVESP) and left ventricular end-diastolic pressure (LVEDP). Blood samples were obtained for biochemical investigations and the hearts were removed for

Evans blue/tetrazolium chloride (TTC) staining and western blotting.

Tissue staining. The LAD coronary artery was religated following I/R and 2–3 ml 2% Evans blue solution (Wokai, Shanghai, China) was transcardially perfused. The rats were administered with KCl solution via a marginal ear vein, and the heart was stopped in diastole. The heart was subsequently removed, washed with saline, and maintained at -20°C for 30–60 min, prior to being divided into six 2-mm sections. The sections were stained with 1% TTC (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) at 37°C and images were captured using a digital camera (D3000; Nikon, Tokyo, Japan). The area at risk (AAR; red staining) indicating the ischemic area, the infarct area (IA; white staining) and non-ischemic area (blue staining) were analyzed using an Image Analysis system (Image Pro Plus 6.0; Media Cybernetics, Inc., Rockville, MD, USA). Infarct size was defined as a percentage of IA to AAR (%).

Detection of creatine kinase (CK), lactate dehydrogenase (LDH), SOD and malondialdehyde (MDA). Following reperfusion, blood samples (5–8 ml/mouse) were collected from the carotid artery and serum was obtained by centrifugation (1,111 × g, 10 min, 4°C). Commercial assay kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) were used to detect the activities of CK (cat. no. A032), SOD (cat. no. A001-3), LDH (cat. no. A020-1) and MDA (cat. no. A003-1) in the serum, according to the manufacturer's protocol.

Western blot analysis. Total proteins were extracted from the AAR tissues using radioimmunoprecipitation assay lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, pH 7.4) (Beyotime Institute of Biotechnology, Haimen, China) and protein concentrations were determined using a Bichinchoninic Acid Protein Assay kit (Beyotime Institute of Biotechnology). Subsequently, 40 µg protein was separated by 10 or 13% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes (EMD Millipore, Bedford, MA, USA). The membranes were blocked with 5% nonfat milk or 1% bovine serum albumin (Amresco, Framingham, MA, USA), and then incubated with the following primary antibodies at 4°C overnight: Rabbit anti-rat cleaved-caspase-3 polyclonal antibody (pAb) (1:1,000 dilution; cat. no. WL0146); rabbit anti-rat cleaved-caspase-9 pAb (1:1,000 dilution; cat. no. WL0191); rabbit anti-rat phosphatidylinositol 3-kinase (PI3K) p85 pAb (1:1,000 dilution; cat. no. WL0191); rabbit anti-rat phosphorylated (p)-Akt pAb (1:1,000 dilution; cat. no. WLP001); rabbit anti-rat Akt pAb (1:1,000 dilution; cat. no. WL0003) (all Wanleibio, Shenyang, China) and rabbit anti-rat p-PI3K p85 pAb (1:500 dilution; cat. no. bs-5538R; Bioss, Beijing, China). The membranes were then washed with Tris-buffered saline containing Tween 20 (Beijing Solarbio Science & Technology Co., Ltd.), and incubated with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (1:5,000, Beyotime Institute of Biotechnology) at 37°C for 45 min. Band densities were analyzed using Gel-Pro Analyzer software 4.0 (Media Cybernetics, Inc.) and normalized to β-actin.




Figure 1. Effects of CG on cardiac function. Following reperfusion, hemodynamic parameters including (A) EF, (B) FS, (C) LVEDP and (D) LVESP were detected, in order to determine cardiac function. Data are expressed as the mean \pm standard deviation ($n=6$ /group). * $P<0.05$ and ** $P<0.01$, compared with the I/R group. ns, not significant; CG, calycosin-7-O- β -d-glucoside; I/R, ischemia-reperfusion; H-CG, high dose CG; L-CG, low dose CG; EF, ejection fraction; FS, fractional shortening; LVEDP, left ventricular end-diastolic pressure; LVESP, left ventricular end-systolic pressure.

Detection of caspase-3/9 activity. Caspase-3/9 activity was measured using a Caspase Activity Assay kit (Beyotime Institute of Biotechnology), according to the manufacturer's protocol. Briefly, the total cellular proteins were quantified and reacted with the corresponding substrates: Ac-DEVD-pNA or Ac-LEHD-pNA. Caspase-3/9 activity was subsequently measured as the optical density of the cleaved substrate pNA at 405 nm using a microplate reader (ELX-800; Bio-Tek Instruments, Inc., Winooski, VT, USA).

PI3K/Akt signaling pathway. The rats were randomly divided into three groups of 12: The I/R group, I/R+H-CG group and I/R+H-CG+LY294002 group. The PI3K inhibitor, LY294002, (0.3 mg/kg body weight; Sigma-Aldrich) was administered to the rats in the I/R+H-CG+LY294002 group via intravenous injection 30 min prior to the administration of H-CG. The rats were then subjected to I/R. Heart tissues from the AAR was lysed with lysis buffer and the expression levels of PI3K p85, p-PI3K p85, Akt and p-Akt were measured using western blot analysis. Infarct size was assessed using Evans blue/TTC double staining. The serum was obtained and levels of CK, SOD, LDH and MDA were analyzed using commercial kits (Nanjing Jiancheng Bioengineering Institute) as described above.

Statistical analysis. GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA) was used for statistical analysis and image processing. Data are expressed as the mean \pm standard deviation. Comparisons between the experimental groups were conducted using one-way analysis of variance, followed by a Bonferroni post-hoc test. $P<0.05$ was considered to indicate a statistically significant difference.

Results

CG ameliorates I/R-induced cardiac dysfunction. Ultrasound analysis was performed to detect cardiac function. As shown in Fig. 1, H-CG had no effect on EF (Fig. 1A), FS (Fig. 1B), LVEDP (Fig. 1C) or LVESP (Fig. 1D), in the sham+H-CG group, compared with the sham group. However, EF, FS and LVESP levels were markedly lower in the I/R group, compared with those in the sham group ($P<0.01$), whereas LVEDP was significantly higher, compared with the sham group ($P<0.01$). Following treatment with H-CG, EF, FS and LVESP ($P<0.05$) were significantly increased, whereas the LVEDP was decreased ($P<0.01$).

CG reduces myocardial infarct size. To determine whether CG affected myocardial infarct size, the rats were pretreated with L-CG or H-CG, and then subjected to I/R. As shown in Fig. 2, no ischemic and necrotic areas were detected in the sham or the sham+H-CG groups. I/R significantly increased the infarct size (29.98 ± 5.28 , vs. 0%; $P<0.01$). As expected, compared with the I/R group ($29.98\pm5.28\%$), the infarct size was significantly smaller in the I/R+L-CG group (22.74 ± 4.00 ; $P<0.05$) and the I/R+H-CG group ($16.22\pm5.15\%$; $P<0.01$).

CG attenuates I/R-induced myocardial injury and oxidative stress-induced damage. The effects of CG were also evaluated on I/R-induced myocardial injury and damaged from oxidative stress. The activities of serum CK (Fig. 3A; $P<0.01$) and LDH (Fig. 3B; $P<0.01$) were markedly elevated in the I/R group, compared with those in the sham group. Following treatment with L-CG, only CK activity was inhibited ($P<0.01$); however, treatment with H-CG markedly inhibited the activities of the two




Figure 2. Effects of CG on infarct size. Following 45 min ischemia and 3 h reperfusion, heart tissues were collected and stained with Evans blue/tetrazolium chloride staining. The AAR is characterized by red staining, indicating the ischemic area, the IA displays white staining and the non-ischemic area exhibits blue staining. Myocardial infarct size is expressed as a percentage of the IA to AAR. Data are expressed as the mean \pm standard deviation ($n=6$ /group). * $P<0.05$ and ** $P<0.01$, compared with the I/R group. CG, calycosin-7-O- β -d-glucoside; I/R, ischemia-reperfusion; H-CG, high dose CG; L-CG, low dose CG; IA, infarct area; AAR, area at risk.




Figure 3. CG suppresses CK and LDH activities, and ameliorates oxidative stress. Following reperfusion, blood was collected and serum was obtained. Subsequently, the activities of (A) CK, (B) LDH and (C) SOD, and (D) MDA content were measured. Data are expressed as the mean \pm standard deviation ($n=6$ /group). ** $P<0.01$, compared with the I/R group. ns, not significant; CG, calycosin-7-O- β -d-glucoside; I/R, ischemia-reperfusion; H-CG, high dose CG; L-CG, low dose CG; CK, creatine kinase; LDH, lactate dehydrogenase; SOD, superoxide dismutase; MDA, malondialdehyde.

markers ($P<0.01$). The activity of SOD, (Fig. 3C; $P<0.01$) was significantly lower in the I/R group, compared with the sham group. By contrast, MDA content (Fig. 3D; $P<0.01$) was significantly higher, compared with the sham group. Pretreatment with H-CG effectively increased the activity of SOD ($P<0.01$) and decreased levels of MDA ($P<0.01$).

CG reduces the I/R-induced increased expression levels and activities of pro-apoptotic factors. The results of the present study demonstrated that caspase cleavage (Fig. 4A; $P<0.01$), and the activities of caspase-3 (Fig. 4B; $P<0.01$) and caspase-9 (Fig. 4C; $P<0.01$) were enhanced in the I/R group, compared

with those in the sham group. Treatment with L-CG and H-CG markedly downregulated the levels of cleaved-caspase-3 ($P<0.01$) and cleaved-caspase-9 (L-CG, $P<0.05$; H-CG, $P<0.01$). In addition, caspase activity was significantly inhibited following treatment with L-CG (caspase-3, $P<0.01$; caspase-9, $P<0.05$) or H-CG ($P<0.01$).

CG increases the phosphorylation of PI3K p85 and Akt. The protein expression levels of p-PI3K p85 (Fig. 5A; $P<0.01$) and p-Akt (Fig. 5B, $P<0.01$) were downregulated in the I/R group, compared with the sham group, and were upregulated in the I/R+L-CG group (p-PI3K p85, $P<0.05$; p-Akt, $P>0.05$)




Figure 4. Effects of CG on the expression levels of apoptosis-associated proteins. Total proteins were extracted from the area at risk tissues, and the expression levels of (A) cleaved-caspase-3 and cleaved-caspase-9 were detected using western blotting. Band density was measured and normalized to that of β-actin. Data are expressed as the mean ± standard deviation (n=5/group). In addition, the activities of (B) caspase-3 and (C) caspase-9 were measured. Data are expressed as the mean ± standard deviation (n=6/group). *P<0.05 and **P<0.01, compared with the I/R group. CG, calycosin-7-O-β-d-glucoside; I/R, ischemia-reperfusion; H-CG, high dose CG; L-CG, low dose CG.




Figure 5. Effects of CG on the expression levels of PI3K/Akt. Total proteins were extracted from the area at risk tissues, and the expression levels of (A) PI3K p85, p-PI3K p85, (B) Akt and p-Akt were detected using western blotting. Band density was measured and normalized to that of β-actin. Data are expressed as the mean ± standard deviation (n=5/group). *P<0.05 and **P<0.01, compared with the I/R group. ns, not significant; CG, calycosin-7-O-β-d-glucoside; I/R, ischemia-reperfusion; H-CG, high dose CG; L-CG, low dose CG; PI3K, phosphatidylinositol 3-kinase; p-, phosphorylated.

and I/R+H-CG group (P<0.01). No statistical differences were observed between the groups in the expression levels of total PI3K p85 or total Akt.

LY294002 inhibits H-CG-induced activation of the PI3K/Akt pathway. To confirm that CG attenuated I/R injury *in vivo* via activation of the PI3K/Akt pathway, the PI3K inhibitor, LY294002, was administered to the rats prior to H-CG. Treatment with H-CG significantly increased the phosphorylation of PI3K and Akt (Fig. 6A; P<0.01); however, suppressing PI3K

activity with LY294002 effectively inhibited H-CG-induced PI3K/Akt phosphorylation (P<0.01). Treatment with H-CG significantly decreased infarct size, compared with the I/R group (15.67±3.28, vs. 35.46±5.33%, respectively; P<0.01), as shown in Fig. 6B, however, infarct size was significantly higher in the I/R+H-CG+LY294002 group, compared with that in the I/R+H-CG group (27.81±4.10, vs. 15.67±3.28%, respectively; P<0.01). Treatment with H-CG significantly decreased CK activity (Fig. 6C; P<0.01), LDH activity (P<0.01) and MDA content (P<0.01), and significantly increased SOD activity




Figure 6. Inhibition of PI3K by LY294002 abrogates CG-induced protection against I/R injury. LY294002 (0.3 mg/kg body weight) was administered to the rats 30 min prior to the administration of CG. Subsequently, the rats were subjected to I/R. Levels of (A) PI3K p85, p-PI3K p85, Akt and p-Akt were detected using western blotting. β -actin was used as an internal control. (B) Infarct size was examined using Evans blue/tetrazolium chloride staining. (C) Activities of CK, LDH and SOD, and MDA content were detected using assay kits. Data are expressed as the mean \pm standard deviation (n=6/group). **P<0.01, compared with the I/R group; &P<0.05 and &&P<0.01, compared with the I/R+H-CG+LY294002 group. CG, calycosin-7-O- β -d-glucoside; I/R, ischemia-reperfusion; H-CG, high dose of CG; PI3K, phosphatidylinositol 3-kinase; p-, phosphorylated; IA, infarct area; AAR, area at risk; CK, creatine kinase; LDH, lactate dehydrogenase; SOD, superoxide dismutase; MDA, malondialdehyde.

(P<0.01). However, co-treatment with LY294002 attenuated these effects (CK, P<0.01; LDH, P<0.05; MDA, P<0.05; SOD, P<0.05).

Discussion

AMI is a leading contributor to morbidity and mortality rates worldwide (23-25). Reperfusion improves clinical symptoms in patients with AMI (26); however, restoration of blood flow following ischemia may result in I/R injury (27,28), which is involved in the development of myocardial necrosis, arrhythmia, myocardial stunning, endothelial dysfunction and microvascular

complications (26,29). The present study demonstrated that CG may exert a cardioprotective effect in a rat model of I/R-induced injury via the PI3K/Akt signaling pathway.

Previous studies have indicated that myocardial I/R injury alters hemodynamic parameters and affects cardiac function (30,31). In addition, levels of EF, FS (32,33) and LVSP are lower in I/R groups than in sham groups, whereas, LVEDP levels are higher (34,35), which is in agreement with the results of the present study. The present study also demonstrated that treatment with H-CG significantly restored the I/R-induced downregulation of EF, FS and LVESP, and markedly lowered the levels of LVEDP in the I/R+H-CG group, compared with the

I/R group. These results suggested that CG improved cardiac function in the rat model of I/R.

Myocardial infarct size is an indicator of myocardial injury, and I/R has been reported to result in infarction in MI/R groups, compared with sham groups (36,37). Treatment with CG has been shown to significantly reduce infarct volume in a rat model of middle cerebral artery occlusion cerebral I/R injury (22). Consistently, the present study observed that L-CG and H-CG efficiently decreased infarct size.

LDH (38) and CK (39) are often elevated in MI, and are used to assess the degree of myocardial injury. Numerous evidence has demonstrated that I/R often induces the generation of reactive oxygen species (ROS) and oxidative stress (40-42). Subsequently, ROS interacts with cell membrane lipids and produces MDA, which impairs cardiac function and induces myocardial cell injury (43,44). Therefore, reducing oxidative stress is an advantageous strategy for the alleviation of I/R injury. In the present study, CK and LDH activity, and MDA content were increased in the I/R group, compared with in the sham group; however, SOD activity was decreased, which was consistent with the results of previous studies (37,45). These results indicated that CG exerted its cardioprotective effects by notably decreasing CK, LDH and MDA, and increasing SOD activity.

Apoptosis is important in development and tissue homeostasis (46), and caspases are considered the executioners of apoptosis (47). Once cells receive apoptotic stimuli, the mitochondrial outer membrane becomes permeabilized and cytochrome *c* is released from the mitochondria into the cytosol (48). Cytochrome *c* interacts with apoptotic protease activating factor 1 and procaspase-9, which is cleaved into caspase-9 and initiates the activation of caspase-3, caspase-6 and caspase-7 (49). Previous studies have reported that I/R injury is associated with the apoptosis of cardiomyocytes (50,51). The present study demonstrated that the expression levels of cleaved-caspase-3 and cleaved-caspase-9, and caspase activity were downregulated in the I/R+L-CG and I/R+H-CG groups, compared with in the I/R group. Therefore, CG may alleviate I/R injury by suppressing caspase activity and inhibiting cardiomyocyte apoptosis.

PI3K consists of a catalytic subunit (p110) and a regulatory subunit (p85) (52,53). Akt is a serine-threonine kinase and, following phosphorylation, performs its antiapoptotic effects via the activation of B-cell lymphoma-2-associated death promoter and caspases (54). Previous studies have reported that the PI3K/Akt signaling pathway is crucial in protecting the myocardium from MI/R injury (55), and the activation of PI3K/Akt significantly reduces cardiomyocyte apoptosis (56). The present study examined the expression levels of PI3K p85, p-PI3K p85, Akt and p-Akt. Pretreatment with CG effectively activated and phosphorylated PI3K and Akt, whereas the levels of total PI3K p85 and Akt were not changed. The PI3K inhibitor, LY294002, was used to determine whether the PI3K/Akt pathway was involved in the CG-mediated alleviation of I/R injury. Suppressing PI3K activity with LY294002 reversed the beneficial effects of CG. Based on the above results, it was hypothesized that CG alleviates I/R injury by activating the PI3K/Akt signaling pathway.

In conclusion, the results of the present study demonstrated that CG attenuated myocardial I/R injury in the rat model.

The protective effects may be associated with activation of the PI3K/Akt pathway, and the inhibition of oxidative stress and pro-apoptotic factors.

Acknowledgements

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 81171404 and 81201093).

References

1. Murray CJ and Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. *Lancet* 349: 1269-1276, 1997.
2. White HD and Chew DP: Acute myocardial infarction. *Lancet* 372: 570-584, 2008.
3. Betgem RP, de Waard GA, Nijveldt R, Beek AM, Escaned J and van Royen N: Intramyocardial haemorrhage after acute myocardial infarction. *Nat Rev Cardiol* 12: 156-167, 2015.
4. Lincoff AM and Topol EJ: Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? *Circulation* 88: 1361-1374, 1993.
5. Hartwell D, Colquitt J, Loveman E, Clegg AJ, Brodin H, Waugh N, Royle P, Davidson P, Vale L and MacKenzie L: Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: Systematic review and economic evaluation. *Health Technol Assess* 9: 1-99, 2005.
6. Luo J, Xu H and Chen KJ: Potential benefits of Chinese Herbal Medicine for elderly patients with cardiovascular diseases. *J Geriatr Cardiol* 10: 305-309, 2013.
7. Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Watt S and Martin-Rendon E: Stem cell treatment for acute myocardial infarction. *Cochrane Database Syst Rev* 2: CD006536, 2012.
8. Abela CB and Homer-Vanniasinkham S: Clinical implications of ischaemia-reperfusion injury. *Pathophysiology* 9: 229-240, 2003.
9. Yu KZ, Liu J, Guo BL, Zhao ZZ, Hong H, Chen HB and Cai SQ: Microscopic research on a multi-source traditional Chinese medicine, *Astragali Radix*. *J Nat Med* 68: 340-350, 2014.
10. Ismail ZM, Amin NM, Yacoub MF and Mohamed AM: Myelo-enhancement by *astragalus membranaceus* in male albino rats with chemotherapy myelo-suppression. *Histological and immunohistochemical study*. *Int J Stem Cells* 7: 12-22, 2014.
11. Liu XB, Ma L, Zhang AH, Zhang YH, Jiang J, Ma W, Zhang LM, Ren WC and Kong XJ: High-throughput analysis and characterization of *Astragalus membranaceus* transcriptome using 454 GS FLX. *PLoS One* 9: e95831, 2014.
12. Jin Y, Chen Q, Li X, Fan X and Li Z: *Astragali Radix* protects myocardium from ischemia injury by modulating energy metabolism. *Int J Cardiol* 176: 1312-1315, 2014.
13. Xu X, Li F, Zhang X, Li P, Zhang X, Wu Z and Li D: *In vitro* synergistic antioxidant activity and identification of anti-oxidant components from *Astragalus membranaceus* and *Paeonia lactiflora*. *PLoS One* 9: e96780, 2014.
14. Luo Y, Qin Z, Hong Z, Zhang X, Ding D, Fu JH, Zhang WD and Chen J: Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia. *Neurosci Lett* 363: 218-223, 2004.
15. Ko JK and Chik CW: The protective action of radix *Astragalus membranaceus* against hapten-induced colitis through modulation of cytokines. *Cytokine* 47: 85-90, 2009.
16. Ma XQ, Shi Q, Duan JA, Dong TT and Tsim KW: Chemical analysis of *Radix Astragali* (Huangqi) in China: A comparison with its adulterants and seasonal variations. *J Agric Food Chem* 50: 4861-4866, 2002.
17. Yu H, Zhang WL, Ding X, Zheng KY, Ho CM, Tsim KW and Lee YK: Optimizing combinations of flavonoids deriving from *astragali radix* in activating the regulatory element of erythropoietin by a feedback system control scheme. *Evid Based Complement Alternat Med* 2013: 541436, 2013.
18. Zheng KY, Choi RC, Cheung AW, Guo AJ, Bi CW, Zhu KY, Fu Q, Du Y, Zhang WL, Zhan JY, et al: Flavonoids from *Radix Astragali* induce the expression of erythropoietin in cultured cells: A signaling mediated via the accumulation of hypoxia-inducible factor-1 α . *J Agric Food Chem* 59: 1697-1704, 2011.

19. Lin LZ, He XG, Lindenmaier M, Nolan G, Yang J, Cleary M, Qiu SX and Cordell GA: Liquid chromatography-electrospray ionization mass spectrometry study of the flavonoids of the roots of *Astragalus mongholicus* and *A. membranaceus*. *J Chromatogr A* 876: 87-95, 2000.
20. Li W, Sun YN, Yan XT, Yang SY, Kim S, Lee YM, Koh YS and Kim YH: Flavonoids from *Astragalus membranaceus* and their inhibitory effects on LPS-stimulated pro-inflammatory cytokine production in bone marrow-derived dendritic cells. *Arch Pharm Res* 37: 186-192, 2014.
21. Pan H, Wang Y, Zhang Y, Zhou T, Fang C, Nan P, Wang X, Li X, Wei Y and Chen J: Phenylalanine ammonia lyase functions as a switch directly controlling the accumulation of calycosin and calycosin-7-*O*-beta-D-glucoside in *Astragalus membranaceus* var. *mongholicus* plants. *J Exp Bot* 59: 3027-3037, 2008.
22. Fu S, Gu Y, Jiang JQ, Chen X, Xu M, Chen X and Shen J: Calycosin-7-*O*-beta-D-glucoside regulates nitric oxide /caveolin-1/matrix metalloproteinases pathway and protects blood-brain barrier integrity in experimental cerebral ischemia-reperfusion injury. *J Ethnopharmacol* 155: 692-701, 2014.
23. Ozaki K, Inoue K, Sato H, Iida A, Ohnishi Y, Sekine A, Sato H, Odashiro K, Nobuyoshi M, Hori M, *et al*: Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion *in vitro*. *Nature* 429: 72-75, 2004.
24. Timmers L, Sluiter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, *et al*: Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. *Circ Res* 102: 257-264, 2008.
25. Zou Y, Takano H, Mizukami M, Akazawa H, Qin Y, Toko H, Sakamoto M, Minamino T, Nagai T and Komuro I: Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. *Circulation* 108: 748-753, 2003.
26. Moens AL, Claeys MJ, Timmermans JP and Vrints CJ: Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. *Int J Cardiol* 100: 179-190, 2005.
27. Prasad A, Stone GW, Holmes DR and Gersh B: Reperfusion injury, microvascular dysfunction and cardioprotection: The 'dark side' of reperfusion. *Circulation* 120: 2105-2112, 2009.
28. Ahmed LA, Salem HA, Attia AS and El-Sayed ME: Enhancement of amlodipine cardioprotection by quercetin in ischaemia/reperfusion injury in rats. *J Pharm Pharmacol* 61: 1233-1241, 2009.
29. Buja LM and Weerasinghe P: Unresolved issues in myocardial reperfusion injury. *Cardiovasc Pathol* 19: 29-35, 2010.
30. Ali N, Rizwi F, Iqbal A and Rashid A: Induced remote ischemic pre-conditioning on ischemia-reperfusion injury in patients undergoing coronary artery bypass. *J Coll Physicians Surg Pak* 20: 427-431, 2010.
31. Toldo S, Seropian IM, Mezzaroma E, Van Tassell BW, Salloum FN, Lewis EC, Voelkel N, Dinarello CA and Abbate A: Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. *J Mol Cell Cardiol* 51: 244-251, 2011.
32. Fan Q, Chen M, Zuo L, Shang X, Huang MZ, Ciccirelli M, Raake P, Brinks H, Chuprun KJ, Dorn GW II, *et al*: Myocardial ablation of G protein-coupled receptor kinase 2 (GRK2) decreases ischemia/reperfusion injury through an anti-intrinsic apoptotic pathway. *PLoS One* 8: e66234, 2013.
33. Zhou YC, Liu B, Li YJ, Jing LL, Wen G, Tang J, Xu X, Lv ZP and Sun XG: Effects of buyang huanwu decoction on ventricular remodeling and differential protein profile in a rat model of myocardial infarction. *Evid Based Complement Alternat Med* 2012: 385247, 2012.
34. Song CL, Liu B, Diao HY, Shi YF, Li YX, Zhang JC, Lu Y, Wang G, Liu J, Yu YP, *et al*: The protective effect of microRNA-320 on left ventricular remodeling after myocardial ischemia-reperfusion injury in the rat model. *Int J Mol Sci* 15: 17442-17456, 2014.
35. Zhao G, Wang S, Wang Z, Sun A, Yang X, Qiu Z, Wu C, Zhang W, Li H, Zhang Y, *et al*: CXCR6 deficiency ameliorated myocardial ischemia/reperfusion injury by inhibiting infiltration of monocytes and IFN- γ -dependent autophagy. *Int J Cardiol* 168: 853-862, 2013.
36. Wang Y, Li X, Wang X, Lau W, Wang Y, Xing Y, Zhang X, Ma X and Gao F: Ginsenoside Rd attenuates myocardial ischemia/reperfusion injury via Akt/GSK-3 β signaling and inhibition of the mitochondria-dependent apoptotic pathway. *PLoS One* 8: e70956, 2013.
37. Han J, Wang D, Yu B, Wang Y, Ren H, Zhang B, Wang Y and Zheng Q: Cardioprotection against ischemia/reperfusion by licochalcone B in isolated rat hearts. *Oxid Med Cell Longev* 2014: 134862, 2014.
38. Kemp M, Donovan J, Higham H and Hooper J: Biochemical markers of myocardial injury. *Br J Anaesth* 93: 63-73, 2004.
39. Singh G, Rohilla A, Singh M and Balakumar P: Possible role of JAK-2 in attenuated cardioprotective effect of ischemic preconditioning in hyperhomocysteinemic rat hearts. *Yakugaku Zasshi* 129: 523-535, 2009.
40. Petrosillo G, Ruggiero FM, Di Venosa N and Paradies G: Decreased complex III activity in mitochondria isolated from rat heart subjected to ischemia and reperfusion: Role of reactive oxygen species and cardiolipin. *FASEB J* 17: 714-716, 2003.
41. Shimouchi A, Yokota H, Ono S, *et al*: Neuroprotective effect of water-dispersible hesperetin in retinal ischemia reperfusion injury. *Jpn J Ophthalmol*: Sept 25, 2015 (Epub ahead of print). doi: 10.1007/s10384-015-0415-z.
42. Wang AL, Niu Q, Shi N, *et al*: Glutamine ameliorates intestinal ischemia-reperfusion injury in rats by activating the Nrf2/Are signaling pathway. *Int J Clin Exp Pathol* 8: 7896-7904, 2015.
43. Kalaycioglu S, Sinci V, Imren Y and Oz E: Metoprolol prevents ischemia-reperfusion injury by reducing lipid peroxidation. *Jpn Circ J* 63: 718-721, 1999.
44. Dhalla NS, Elmoselhi AB, Hata T and Makino N: Status of myocardial antioxidants in ischemia-reperfusion injury. *Cardiovasc Res* 47: 446-456, 2000.
45. Zhang S, Li H and Yang SJ: Tribulosin protects rat hearts from ischemia/reperfusion injury. *Acta Pharmacol Sin* 31: 671-678, 2010.
46. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA and Yuan J: Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. *Nature* 403: 98-103, 2000.
47. Riedl SJ and Shi Y: Molecular mechanisms of caspase regulation during apoptosis. *Nat Rev Mol Cell Biol* 5: 897-907, 2004.
48. Waterhouse NJ, Goldstein JC, von Ahsen O, Schuler M, Newmeyer DD and Green DR: Cytochrome *c* maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process. *J Cell Biol* 153: 319-328, 2001.
49. Denault JB, Eckelman BP, Shin H, Pop C and Salvesen GS: Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9. *Biochem J* 405: 11-19, 2007.
50. Hamacher-Brady A, Brady NR, Logue SE, Sayen MR, Jinno M, Kirshenbaum LA, Gottlieb RA and Gustafsson AB: Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy. *Cell Death Differ* 14: 146-157, 2007.
51. Zhang W, Xing B, Yang L, Shi J and Zhou X: Icaritin attenuates myocardial ischemia and reperfusion injury via anti-inflammatory and anti-oxidative stress effects in rats. *Am J Chin Med* 43: 1083-1097, 2015.
52. Shin YK, Liu Q, Tikoo SK, Babiuk LA and Zhou Y: Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K. *J Gen Virol* 88(Pt 1): 13-18, 2007.
53. Ray PD, Huang BW and Tsuji Y: Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cell Signal* 24: 981-990, 2012.
54. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, Edgerton ME, Ninan M, Andersen JJ and Gonzalez AL: Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. *Am J Respir Crit Care Med* 170: 1088-1094, 2004.
55. Zhang Y, Wei L, Sun D, Cao F, Gao H, Zhao L, Du J, Li Y and Wang H: Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. *Diabetes Obes Metab* 12: 316-322, 2010.
56. Fujio Y, Nguyen T, Wencker D, Kitsis RN and Walsh K: Akt promotes survival of cardiomyocytes *in vitro* and protects against ischemia-reperfusion injury in mouse heart. *Circulation* 101: 660-667, 2000.